Investor Relations

News
Events and Presentations
Financials
Shareholder Information
Environmental, Social and Governance
Additional Resources

Menu

Visit Teva Global website

News
Events and Presentations
Financials
Shareholder Information
Environmental, Social and Governance
Additional Resources

Home Investors > Events and Presentations > Events & Presentations > Event Details

Event Details

Duvakitug (Anti-TL1A) Phase 2b additional data presentation after ECCO – Conference call

February 24, 2025 8:00 AM ET

Webcast (opens in new window)
Presentation (opens in new window)

Quick links

Quarterly Results
Events and Presentations
Shareholder Meetings
ESG
Debt Securities
SEC Filings
Investor FAQ

Email alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Teva Pharmaceutical Industries Ltd., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Teva Pharmaceutical Industries Ltd. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Mailing Lists *

Press Releases

Events

SEC Filings

Financial Reports